The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system and thus improving the lives of millions of patients worldwide.
EDITOR OF THE MONTH
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital.
Read More
Read More
EDITOR OF THE MONTH
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital.
Editor of the month
Prof. Dr. Sven Francque obtained his MD at the University of Antwerp, Belgium, in 1994 and was subsequently trained in internal medicine and in gastroenterology and hepatology at the Antwerp University Hospital, Belgium and at the Department of Hepatology of the Beaujon hospital, Clichy, France.
PROF. DR. SVEN FRANCQUE
LATEST ARTICLES
NASH: bariatric surgery and major adverse liver and cardiovascular outcomes
In this retrospective cohort study of 1158 patients with biopsy-proven fibrotic NASH without cirrhosis, bariatric surgery was significantly associated with a lower risk of major adverse liver outcomes.
Latest Videos
Latest articles from PubMed
- Liver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
- Hepatic Stellate Cell-Immune Interactions in NASH
- Screening New Blood Indicators for Non-alcoholic Fatty Liver Disease (NAFLD) Diagnosis of Chinese Based on Machine Learning
- The benefit of probiotics in pediatric non-alcoholic fatty liver disease: a meta-analysis of randomized control trials
- Letter to the Editor: The novel perspectives of GLP-1/GLP-2 receptors against NASH via the diverse regulation
- Abdominal obesity phenotypes are associated with the risk of developing non-alcoholic fatty liver disease: insights from the general population
- Comparison of the diagnostic value between triglyceride-glucose index and triglyceride to high-density lipoprotein cholesterol ratio in metabolic-associated fatty liver disease patients: a retrospective cross-sectional study
- Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy
sign up for our newsletter
The PanNASH Initiative aims to increase awareness and disseminate knowledge related to NASH as a multisystem disease with a focus on PPAR agonists among the scientific and clinical community, patients and other key stakeholders within the healthcare system, thus improving the lives of millions of patients worldwide.
Subscribe to us and get new updates